Key Points
- Director Kong Yiu Cheung purchased 2.5 million NewGenIvf shares at an average of $1.00 each, investing $2.5 million and increasing his direct ownership by 204.55% to 3,722,223 shares.
- NewGenIvf shares opened at $1.21 after falling 9%, near the company’s 52-week low of $1.15 and well below its 50-day and 200-day moving averages.
- Analyst sentiment remains negative: one analyst rates the stock “Sell,” while the overall MarketBeat consensus is also “Sell,” despite one recent “Hold” upgrade.
NewGenIvf Group Limited (NASDAQ:NIVF - Get Free Report) Director Kong Yiu Cheung bought 222,223 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average cost of $1.50 per share, with a total value of $333,334.50. Following the purchase, the director directly owned 222,223 shares of the company's stock, valued at $333,334.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Kong Yiu Cheung also recently made the following trade(s):
- On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The stock was purchased at an average cost of $1.00 per share, with a total value of $2,500,000.00.
- On Thursday, June 18th, Kong Yiu Cheung bought 500,000 shares of NewGenIvf Group stock. The stock was purchased at an average cost of $1.33 per share, for a total transaction of $665,000.00.
NewGenIvf Group Stock Down 9.0%
Shares of NIVF opened at $1.21 on Thursday. The firm has a 50 day moving average price of $2.87 and a 200-day moving average price of $11.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. NewGenIvf Group Limited has a fifty-two week low of $1.15 and a fifty-two week high of $1,539.00.
Analyst Upgrades and Downgrades
NIVF has been the subject of several recent research reports. Weiss Ratings reiterated a "sell (d)" rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen upgraded shares of NewGenIvf Group to a "hold" rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, NewGenIvf Group presently has a consensus rating of "Sell".
View Our Latest Research Report on NIVF
NewGenIvf Group Company Profile
(
Get Free Report)
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People's Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF's service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
